BioTech
-
PTC, Dyne, Rapport, Cytokinetics news
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Cytokinetics CEO stresses company can launch heart drug on its own
As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug,…
Read More » -
Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Live from STAT Breakthrough Summit West
On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme…
Read More » -
STAT+: PDS Biotech’s survival benefit is absurdly overstated
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it…
Read More » -
ALS treatment from Biogen, Ionis fails in study
A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and…
Read More » -
Biogen, Ionis, Johnson & Johnson news
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on results of a Phase 1/2…
Read More » -
Lilly’s weekly insulin works as well as daily products, new studies show
Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage…
Read More » -
Galapagos to make CAR-T therapies at blood centers across U.S.
Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a…
Read More » -
WuXi Biologics execs register to lobby as Congress comes for the company
WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add…
Read More »